Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Focus of Study Instead × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 17 Lung Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Breast Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Squamous Cell 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Adenocarcinoma of Lung 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Cancers of the Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Pathologic Complete Response 1 PFS 1 NSCLC Harboring NRG1 Fusion 1 Focus of Study Instead 1 Carcinoma, Transitional Cell 1 Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1 Advanced Squamous Non Small Cell Lung Cancer 1

Interventions

Gemcitabine 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01728818 2017-07-19

ACCEPT

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Focus of Study Instead

Data powered by HemOnc (CC BY 4.0) Colophon ⚡